Allogene Therapeutics, Inc. — Form 8-K Summary
Report date: March 27, 2020. This Form 8-K reports operational impacts from the COVID-19 pandemic and supplements the company’s previously disclosed risk factors. It does not provide new financial statements or quantitative financial results.
Business Context and Reporting Period
Allogene is developing allogeneic CAR T-cell therapies. The filing addresses the status of clinical trials, research and development operations, and manufacturing activities during the COVID-19 pandemic.
- Servier halted recruitment in the PALL and CALM Phase 1 trials evaluating UCART19 in patients with relapsed or refractory acute lymphoblastic leukemia.
- Allogene continued enrolling patients in the ALPHA trial for ALLO-501 in relapsed or refractory non-Hodgkin lymphoma and the UNIVERSAL trial for ALLO-715 in relapsed or refractory multiple myeloma, although enrollment and follow-up could be affected by COVID-19.
Financial and Operating Metrics
- The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, cash balance, or other quantitative financial metrics.
- Allogene stated that the timing and total business impact of COVID-19 were unknown as of the filing date.
- Construction of Allogene’s manufacturing facility in Newark, California, had been interrupted and could face additional interruptions.
Material Changes Versus the Prior Comparable Period
- Servier halted recruitment in the PALL and CALM trials because of exceptional circumstances related to COVID-19.
- Allogene closed its headquarters, with administrative employees working remotely, and limited staffing in research and development laboratories.
- COVID-19 introduced potential delays to enrollment, patient follow-up, clinical trial activities, preclinical work, regulatory interactions, contract manufacturing, supplies, and manufacturing facility construction.
Guidance, Outlook, Risks, and Unusual Items
- Allogene expected to report initial ALLO-501 trial data in the second quarter of 2020, while cautioning that the timing and conduct of the trial could be affected by the pandemic.
- Disclosed risks include difficulty enrolling or retaining patients, interruptions to clinical-site activities and data collection, diversion of healthcare resources, delays in regulatory operations, supply-chain disruptions, and reduced employee availability.
- The company warned that the pandemic could materially adversely affect its operations, financial condition, results of operations, clinical trials, and preclinical studies.
- Allogene also noted that volatility in biopharmaceutical stock prices could make equity financing more difficult or require unfavorable terms.
- The duration, geographic spread, containment measures, and ultimate impact of COVID-19 were described as highly uncertain.
Key Facts for Investors to Verify
- Whether recruitment and follow-up in the ALPHA and UNIVERSAL trials were delayed, and whether the planned second-quarter 2020 ALLO-501 data release occurred.
- The ultimate duration and operational impact of the PALL and CALM recruitment halt.
- Changes to clinical timelines, patient enrollment, data integrity, and trial costs resulting from COVID-19.
- The status, cost, and completion timeline of the Newark manufacturing facility.
- Allogene’s cash runway, financing needs, and any subsequent capital raises, which are not disclosed in this filing.
- Subsequent SEC filings for updated COVID-19 impacts, financial results, and revised development plans.